Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Subodh Verma

Showing results (421-430 of 616) with videos related to

Pageof 62
Sort By:
Journal of the American College of Cardiology|September 1, 2024
Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF ProgramSubodh Verma, Javed Butler, Barry A Borlaug, et al.
Circulation Research|August 26, 2006
Stem cell factor deficiency is vasculoprotective: unraveling a new therapeutic potential of imatinib mesylateChao-Hung Wang, Nicole Anderson, Shu-Hong Li, et al.
The Canadian Journal of Cardiology|January 25, 2022
Leaflet Resection vs Preservation for Degenerative Mitral Regurgitation: Functional Outcomes and Mitral Stenosis at 12 Months in a Randomized TrialMakoto Hibino, Arjun Pandey, Vincent Chan, et al.
Circulation|October 26, 2018
Rate, Timing, Correlates, and Outcomes of Hemodynamic Valve Deterioration After Bioprosthetic Surgical Aortic Valve ReplacementErwan Salaun, Haïfa Mahjoub, Nicolas Girerd, et al.
The Canadian Journal of Cardiology|December 5, 2009
Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular SocietyDavid Fitchett, John Eikelboom, Stephen Fremes, et al.
European Journal of Heart Failure|June 6, 2023
Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trialMichael Böhm, Javed Butler, Marcin Krawczyk, et al.
Diabetes, Obesity & Metabolism|December 15, 2020
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 studyMikhail Kosiborod, Otavio Berwanger, Gary G Koch, et al.
Journal of the American College of Cardiology|May 10, 2023
Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk CategoriesJaved Butler, Milton Packer, Tariq Jamal Siddiqi, et al.
The Canadian Journal of Cardiology|October 2, 2018
CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes ManagementG B John Mancini, Alice Y Cheng, Kim Connelly, et al.
Cardiovascular Diabetology|August 28, 2024
Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trialMarina Pourafkari, Kim A Connelly, Subodh Verma, et al.
Pageof 62

Showing results (421-430 of 616) with videos related to

Sort By:
Pageof 62
Journal of the American College of Cardiology|September 1, 2024
Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF ProgramSubodh Verma, Javed Butler, Barry A Borlaug, et al.
Circulation Research|August 26, 2006
Stem cell factor deficiency is vasculoprotective: unraveling a new therapeutic potential of imatinib mesylateChao-Hung Wang, Nicole Anderson, Shu-Hong Li, et al.
The Canadian Journal of Cardiology|January 25, 2022
Leaflet Resection vs Preservation for Degenerative Mitral Regurgitation: Functional Outcomes and Mitral Stenosis at 12 Months in a Randomized TrialMakoto Hibino, Arjun Pandey, Vincent Chan, et al.
Circulation|October 26, 2018
Rate, Timing, Correlates, and Outcomes of Hemodynamic Valve Deterioration After Bioprosthetic Surgical Aortic Valve ReplacementErwan Salaun, Haïfa Mahjoub, Nicolas Girerd, et al.
The Canadian Journal of Cardiology|December 5, 2009
Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular SocietyDavid Fitchett, John Eikelboom, Stephen Fremes, et al.
European Journal of Heart Failure|June 6, 2023
Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trialMichael Böhm, Javed Butler, Marcin Krawczyk, et al.
Diabetes, Obesity & Metabolism|December 15, 2020
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 studyMikhail Kosiborod, Otavio Berwanger, Gary G Koch, et al.
Journal of the American College of Cardiology|May 10, 2023
Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk CategoriesJaved Butler, Milton Packer, Tariq Jamal Siddiqi, et al.
The Canadian Journal of Cardiology|October 2, 2018
CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes ManagementG B John Mancini, Alice Y Cheng, Kim Connelly, et al.
Cardiovascular Diabetology|August 28, 2024
Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trialMarina Pourafkari, Kim A Connelly, Subodh Verma, et al.
Pageof 62